SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome ...
Earlier this week at the 2023 Detroit Auto Show, General Motors officially unveiled the all-new, next-generation 2024 GMC Acadia, which will go on sale in the U.S. in early 2024. Now, The General has ...
ACADIA Pharmaceuticals, Inc. (ACAD) Enters Agreement with Biovail Laboratories Inc. to Conclude Collaboration and Regain North American Rights to Pimavanserin; Acadia Receives $8.75 Million SAN DIEGO- ...
At Halifax, Dartmouth and on Cape Breton Island, thirsty Nova Scotians queued up on the sidewalk white shutters came down, doors were opened and government liquor stores began to operate for the first ...
--DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback